Inicio › Cáncer de seno › Texas
Ensayos clínicos de Cáncer de seno en Texas
176 estudios sobre Cáncer de seno buscan participantes en Texas.
Ciudades en Texas
- Houston126 estudios
- Dallas54 estudios
- San Antonio45 estudios
- Austin15 estudios
- Fort Worth14 estudios
- League City12 estudios
- The Woodlands11 estudios
- Sugar Land8 estudios
- Irving8 estudios
- El Paso7 estudios
- Lewisville6 estudios
- Lubbock6 estudios
- Tyler5 estudios
- McAllen4 estudios
- Amarillo4 estudios
- Killeen4 estudios
- Baytown3 estudios
- Abilene3 estudios
- Denton3 estudios
- Arlington3 estudios
- Cypress3 estudios
Texto oficial del estudio (inglés)
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- NEXT Houston, Galveston
- NEXT Oncology - PARENT, San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT07360314Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Baylor College of Medicine, Houston
- MD Anderson Cancer Center, Houston
- Harris Health System - Smith Clinic, Houston
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT05696626A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Renovatio Clinical - El Paso, El Paso
- JPS Health Network, Fort Worth
- Renovatio Clinical, The Woodlands
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT05894239A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- Oncology Consultants PA, Houston
ReclutandoFase 1
Edades de 18 a 55 · Mujeres · Actualizado el 12 nov 2026 · NCT07310420Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
- M D Anderson Cancer Center, Houston
Reclutando
Edades de 18 en adelante · Mujeres · Actualizado el 12 nov 2026 · NCT05649072Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Texas Oncology - DFW ( Site 8000), Dallas
- Houston Methodist Hospital ( Site 0022), Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06797635Multi-center MRD Registry for Inflammatory Breast Cancer
- MD Anderson Cancer Center, Houston
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06966050An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
- Next Oncology Austin, Austin
- The University of Texas Md Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07222267BostonGene and Exigent Genomic INsight Study
- Oncology Consultants, Houston
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06272864S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- UT Southwestern Clinical Center at Richardson/Plano, Richardson
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT03418961Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
- UT MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 12 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT05372640Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
- Research Facility, Dallas
- Research Facility, Houston
ReclutandoFase 1/2
Todas las edades · Todos los sexos · Actualizado el 12 nov 2026 · NCT06590857Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
- UT Southwestern, Dallas
Reclutando
Edades de 18 a 80 · Mujeres · Actualizado el 12 nov 2026 · NCT05245812A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Baylor Scott & White Research Institute -Texas Oncology, Dallas
- UT Southwestern Medical Center, Dallas
- South Texas Accelerated Research Therapeutics (START), LLC, San Antonio
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06827236Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- M D Anderson Cancer Center, Houston
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT03941756A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Texas Oncology - DFW ( Site 8009), Dallas
- UT Southwestern ( Site 0092), Dallas
- Texas Oncology - Northeast Texas ( Site 8002), Flower Mound
- y 6 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06966700Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT04557449ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- University of Texas Southwestern Medical Center, Dallas
- Houston Methodist Cancer Center, Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT07007559Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
- UT Southwestern Medical Center, Dallas
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT05693766Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
- MD Anderson Cancer Center, Houston
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT05964504A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07029399Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT06324357A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center - Conroe, Conroe
- The University of Texas - M.D. Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
- y 3 más
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07318805Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Houston Methodist Hospital, Houston
- Oncology Consultants, Houston
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07214532Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Texas Oncology Central/South, Austin
- Texas Oncology DFW, Dallas
- University of Texas Southwestern Medical Center, Dallas
- y 3 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT06982521A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Hendrick Medical Center, Abilene
- World Research Link, Baytown
- Parkland Health and Hospital System, Dallas
- y 10 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07174336A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- JPS Health Network, Fort Worth
- Community Clinical Trials, Spring
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06790693E-Mindfulness Approaches for Living After Breast Cancer
- The Don and Sybil Harrington Cancer Center, Amarillo
ReclutandoFase 3
Edades de 18 a 50 · Todos los sexos · Actualizado el 4 nov 2026 · NCT06748222A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of Texas MD Anderson Cancer Center, Houston
- Houston Methodist Hospital, Houston
- Oncology Consultants P.A., Houston
- y 1 más
ReclutandoFase 2
Edades de 18 en adelante · Mujeres · Actualizado el 4 nov 2026 · NCT07287098Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT05334069Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Texas Oncology, Abilene
- Texas Oncology - Central / South Texas, Austin
- Mary Crowley Cancer Research, Dallas
- y 3 más
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT05579366A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The University of Texas - MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06400472A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Texas Oncology - DFW (Sammons CC), Dallas
- Baylor College of Medicine, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07213791A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Texas Oncology - DFW (Sammons CC), Dallas
- MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07114601A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06760819Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- The Don and Sybil Harrington Cancer Center, Amarillo
- Houston Methodist San Jacinto Hospital, Baytown
- UT MD Anderson - The Woodlands, Conroe
- y 19 más
ReclutandoFase 3
Edades de 18 a 60 · Mujeres · Actualizado el 4 nov 2026 · NCT05879926A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Texas Oncology - DFW, Dallas
- MD Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06695845A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Texas Oncology - DFW ( Site 8003), Dallas
- JPS Health Network ( Site 0067), Fort Worth
- Texas Oncology - Gulf Coast ( Site 8006), Houston
- y 3 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07060807A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
- South Texas Accelerated Research Therapeutics, LLC (START), San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Mujeres · Actualizado el 3 nov 2026 · NCT07524855A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- MD Anderson Cancer Center, Houston
- NEXT Dallas, Irving
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07578571De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.